Pilulka Lekarny a.s.

Pilulka Lekarny a.s.

PPSECZ:PINK
95.00
CZK
-2.00
(-2.06%)
-14.27EPS
460.14MMarket Cap
Pilulka Lekarny a.s.
PSECZ:PINK
(Prague Stock Exchange)

Recent

price

95.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
CZK
403.49
526.42
704.67
942.2
960.65
787.53
481.86
323.8
Revenue per Share
-10.22
-16.29
-8.65
-10.09
-25.49
-64.63
-46.46
-14.36
Basic EPS, GAAP
- -
- -
-8.02
-22.75
-45.11
-25.83
-16.62
-7.55
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
13.08
34.62
90.17
80.9
55.01
12.13
-34.72
-49.45
Book Value per Share
-12.15
-0.3
68.93
48.12
19.77
-12.74
-49.13
-57.84
Tangible Book Value per Share
3
3
3
3
3
3
3
3
Basic Weighted Avg Shares
1,009
1,316
1,780
2,380
2,447
2,132
1,304
876
Sales/Revenue/Turnover
-2.17
-2.87
0.19
-0.08
-1.85
-6.86
-7.33
-1.07
Operating Margin (%)
- -
- -
19
23
51
74
64
34
Depreciation Expense
-26
-41
-22
-25
-65
-175
-126
-39
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-2.53
-3.09
-1.23
-1.07
-2.65
-8.21
-9.64
-4.43
Profit Margin (%)
-30
-38
-45
-119
-29
-117
-181
-84
Working Capital
- -
- -
- -
- -
25
4
2
1
LT Debt
32
81
218
204
139
31
-97
-138
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-68.29
-13.91
-11.8
-37.7
-202.26
- -
- -
Return on Common Equity (%)

Capital Structure

CZK

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

CZK

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

CZK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-97.75%
42.54%
Free Cash Flow
- -
30.85%
-54.6%
Net Income, GAAP
- -
48.71%
-69.09%
Sales/Revenue/Turnover
- -
-9.6%
-32.8%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CZK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
2,132
2024
- -
342
- -
- -
1,304
2025
- -
- -
- -
- -
876

Quarterly Earnings Per Share

CZK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
-64.63
2024
- -
- -
- -
- -
-46.46
2025
- -
- -
- -
- -
-14.36

Quarterly Dividends Per Share

CZK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Business
Pilulka Lékárny a.s. (PINK.PR) operates as a technology-driven pharmacy group focused on the retail and online distribution of medicinal products, pharmacy goods, cosmetics, dietary supplements, healthy lifestyle items, and related services under the Pilulka brand; it runs brick-and-mortar pharmacies including its own and partner locations, alongside a leading e-commerce platform with portals such as Pilulka.cz, Pilulka.sk, Pilulka.ro, Pilulka.hu, and Pilulka.at offering features like Pilulka Express rapid delivery, dispensing boxes, e-health tools including the Plus Care mobile app, blood and DNA testing subscriptions via Pilulka PRO membership, and Korean Beauty Store selections; the company serves consumer markets in the Czech Republic, Slovakia, Romania, Hungary, and Austria through owned distribution warehouses, franchise networks, and digital services connecting pharmaceutical producers, distributors, health insurers, and healthcare providers. Founded in 2013 and headquartered at Českomoravská 2408/1, Prague 9, Czech Republic, Pilulka Lékárny a.s. acts as the parent of the Pilulka Group encompassing subsidiaries across these regions and listed its shares on the Prague Stock Exchange's START market in October 2020. In recent developments, the company underwent major transformation in 2024 including staff and supplier reductions, halving marketing costs, cutting logistics expenses by 30 percent, and settling most overdue supplier invoices, resulting in turnover declining 36 percent to CZK 1.35 billion amid a 40 percent drop in e-shop orders; it was acquired last year by Tomas Cupr, founder of Rohlik.cz, through his Growth Expert vehicle, with new leadership from Billy and Alza executives appointed in April 2025, and management now plans conservative sales growth targeting EBITDA and cash flow profitability.